

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:

Gary BRIDGER et al.

Patent No.: 7,091,217

Issued: August 15, 2006

For: CHEMOKINE RECEPTOR BINDING
HETEROCYCLIC COMPOUNDS

Confirmation No.: 7291

Art Unit: 1625

Examiner: Rita J. Desai

REQUEST FOR RECONSIDERATION

Decisions & Certificates of Correction Branch
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

A Request for Certificate of Correction pursuant to 37 C.F.R. § 1.323 in the above-referenced patent was submitted on 30 August 2006. The appropriate fee was paid along with that Request. The petition was denied. In a helpful conversation with Ernest C. White, *LJE*, it was clarified that the original Request had failed to indicate the position on page 1 where the omitted material should be inserted. The present paper will attempt to clarify this. A copy of the original Request and the paper denying the Request are attached for the convenience of the Office.

Also attached are copies of the front pages of the above-referenced patent and of the patent issued on the application of which it is a divisional.

The above-referenced patent, U.S. 7,091,217 issued on application No. 10/799,386 filed 11 March 2004 and was a division of application No. 10/031,812 filed on 28 March 2002, which is now U.S. patent 6,734,191 (the '191). The omitted data requested to be inserted would be inserted immediately below the designation of 10/031,812 designated (62) on the face of the above-referenced patent. The enclosed face page of the '191 patent should clarify the position of these data.

Should further clarification be needed, a telephone call to the undersigned is respectfully requested. The consideration shown the undersigned representative of the patentee by Mr. White in a telephone conversation discussing this matter on 19 April 2007 is much appreciated.

In the unlikely event that the transmittal letter is separated from this document and the Patent Office determines that an extension and/or other relief is required, applicants petition for any required relief including extensions of time and authorize the Commissioner to charge the cost of such petitions and/or other fees due in connection with the filing of this document to **Deposit Account No. 03-1952** referencing **docket No. 391442005902**.

Dated: April 19, 2007

Respectfully submitted,

Electronic signature: /Kate H. Murashige/
Kate H. Murashige

Registration No.: 29,959
MORRISON & FOERSTER LLP
12531 High Bluff Drive, Suite 100
San Diego, California 92130-2040
(858) 720-5112

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the U.S. Postal Service on the date shown below with sufficient postage as First Class Mail, in an envelope addressed to:
Attention: Certificate of Correction Branch, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Dated: August 30, 2006

Signature: Judy Bridgwater
(Judy Bridgwater)

Docket No.: 391442005902
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Letters Patent of:
Gary BRIDGER et al.

Patent No.: 7,091,217

Issued: August 15, 2006

For: CHEMOKINE RECEPTOR BINDING
HETEROCYCLIC COMPOUNDS

COPY

**REQUEST FOR CERTIFICATE OF CORRECTION
PURSUANT TO 37 CFR 1.323**

Attention: Certificate of Correction Branch
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Upon reviewing the above-identified patent, Patentee noted an omission which should be corrected.

At page 1: --(22)	PCT Filed:	Sep. 17, 2001
(86)	PCT No.:	PCT/US01/29590
	§ 371 (c)(1),	
	(2), (4) Date:	Mar. 28, 2002
(87)	PCT Pub. No.:	WO02/34745
	PCT Pub. Date:	May 2, 2002--

The error now sought to be corrected was an inadvertent omission on the part of Patentee, the correction of which does not involve new matter or require reexamination.

Please charge our Deposit Account No. 03-1952 in the amount of \$100.00 covering the fee set forth in 37 CFR 1.20(a). Fee Transmittal Form PTO/SB/17 is enclosed in duplicate.

Transmitted herewith is a proposed Certificate of Correction effecting such amendment. Patentee respectfully solicits the granting of the requested Certificate of Correction.

The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 03-1952, under Order No. 391442005902.

Dated: August 29, 2006

Respectfully submitted,

By Kate H. Murashige
Kate H. Murashige
Registration No.: 29,959
MORRISON & FOERSTER LLP
12531 High Bluff Drive, Suite 100
San Diego, California 92130-2040
(858) 720-5112

**UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION**Page 1 of 1

PATENT NO. : 7,091,217
APPLICATION NO. : 10/799,386
ISSUE DATE : August 15, 2006
INVENTOR(S) : Gary BRIDGER et al.

It is certified that an error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

At page 1:

--(22) PCT Filed: **Sep. 17, 2001**
(86) PCT No.: **PCT/US01/29590**
§ 371 (c)(1),
(2), (4) Date: **Mar. 28, 2002**
(87) PCT Pub. No.: **WO02/34745**
PCT Pub. Date: **May 2, 2002--**

MAILING ADDRESS OF SENDER (Please do not use customer number below):

Kate H. Murashige
MORRISON & FOERSTER LLP
12531 High Bluff Drive, Suite 100
San Diego, California 92130-2040



UNITED STATES DEPARTMENT OF COMMERCE
COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, VA 22313-1450

15 HM
Date : 10/2/2006
Patent No. : 7,091,217 B2
Inventor(s) : Bridger et al.
Issue Date : August 15, 2006
Title : CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS
Doc./File No. : 391442005902

Re: Certificate of Correction

Consideration has been given your request for a certificate of correction, for the above-identified patent under the provisions of Rule 1.322 and 1.323.

Respecting the alleged error(s) in your request, there is no record of a claim under 35 U.S.C. 371 for *this* patent. The requested data should be printed, in accordance with FORM PCT/DO/EO/903 (the 903) for this patent, *only* if the ser. no. for this patented file is noted on the 903 of record in this file. Example, the serial number identified on the 903, is "07/971,961". Therefore, no correction is in order here under the provisions of Rule 1.322.

In view of the foregoing, your request for certificate of correction in this matter is hereby denied.

Further consideration will be given concerning this matter upon receipt of a request for **Reconsideration** (reconsideration should be accompanied by supporting document(s) such as, amendment, postcard receipt, 1449/892, etc.) and should be filed and directed to Decisions & Certificates of Correction Branch.

Ernest C. White, LIE (703) 308-9390 ext.#122
Cecelia B. Newman, Supervisor (703) 308-9390 ext. #10²
Decisions & Certificates of Correction Branch

MORRISON & FOERSTER LLP
12531 HIGH BLUFF DRIVE
SUITE 100
SAN DIEGO CA 92130-2040

DOCKETED: Request Reconsider
REMINDER: 11-2-06
FINAL DUE DATE:
fn

ecw



US007091217B2

(12) **United States Patent**
Bridger et al.(10) **Patent No.:** **US 7,091,217 B2**
(45) **Date of Patent:** **Aug. 15, 2006**(54) **CHEMOKINE RECEPTOR BINDING
HETEROCYCLIC COMPOUNDS**(75) **Inventors:** Gary Bridger, Bellingham, WA (US);
Renato Skerlj, Vancouver (CA); Al
Kaller, Vancouver (CA); Curtis
Harwig, White Rock (CA); David
Bogucki, Surrey (CA); Trevor R.
Wilson, Langley (CA); Jason
Crawford, Vancouver (CA); Ernest J.
McEachern, White Rock (CA); Ben
Atsma, Abbotsford (CA); Siqiao Nan,
Richmond (CA); Yuanxi Zhou, Surrey
(CA); Dominique Schols, Herent (BE);
Christopher Dennis Smith, Vancouver
(CA); Maria Rosaria Di Fluri,
Burnaby (CA)(73) **Assignee:** AnorMED, Inc., Langley (CA)(*) **Notice:** Subject to any disclaimer, the term of this
patent is extended or adjusted under 35
U.S.C. 154(b) by 0 days.(21) **Appl. No.:** 10/799,386(22) **Filed:** Mar. 11, 2004(65) **Prior Publication Data**
US 2004/0171638 A1 Sep. 2, 2004**Related U.S. Application Data**(62) Division of application No. 10/031,812, filed on Mar.
28, 2002, now Pat. No. 6,734,191.(60) Provisional application No. 60/234,816, filed on Sep.
22, 2000, provisional application No. 60/234,510,
filed on Sep. 22, 2000, provisional application No.
60/232,891, filed on Sep. 15, 2000, provisional appli-
cation No. 60/233,087, filed on Sep. 15, 2000.(51) **Int. Cl.**
A61K 31/47 (2006.01)
C07D 221/02 (2006.01)(52) **U.S. Cl.** 514/311; 514/314; 546/134;
546/135(58) **Field of Classification Search** 546/134,
546/135; 514/311, 314

See application file for complete search history.

(56) **References Cited****U.S. PATENT DOCUMENTS**5,021,409 A 6/1991 Murrer et al. 514/183
5,583,131 A 12/1996 Bridger et al. 514/183
5,698,546 A 12/1997 Bridger et al. 514/183
5,817,807 A 10/1998 Bridger et al. 540/474
6,001,826 A 12/1999 Murrer et al. 514/183
6,365,583 B1 4/2002 MacFarland et al. 514/183**FOREIGN PATENT DOCUMENTS**JP 11-269146 10/1999
WO 99/38514 8/1999
WO 00/42852 7/2000
WO 00/51697 9/2000
WO 00/56729 9/2000
WO 02/22600 3/2002**OTHER PUBLICATIONS**U.S. Appl. No. 60/172,153, filed Dec. 17, 1999.
U.S. Appl. No. 09/111,895, filed Jul. 8, 1998.
U.S. Appl. No. 09/535,314, filed Mar. 24, 2000.
U.S. Appl. No. 60/172,153, filed Dec. 17, 1999.
U.S. Appl. No. 09/111,895, filed Jul. 8, 1998, Bridger et al.
U.S. Appl. No. 09/535,314, filed Mar. 24, 2000, Bridger et
al.
Abi-Younes et al., *Clin. Res.* 86:131-138 (2000).
Alkhatib et al., *Science* 272:1955-1958 (1996).
Arni et al., *Eur. J. Haematol.* 64:323-332 (2000).
Arenburg et al., *J. Leukocyte Biol.* 62:554-562 (1997).
Aiuti et al., *J. Exp. Med.* 185:111-120 (1997).
Baggiolini, *Nature* 392:565-568 (1998).
Bajetto et al., *J. Neurochem.* 73:2348-2357 (1999).
Berger et al., *Annu. Rev. Immunol.* 17: 657-700 (1999).
Biard-Piechaczyk et al., *Virology* 268:329-344 (2000).
Blaak et al., *Proc. Natl. Acad. Sci.* 97:1269-1274 (2000).
Blanco et al., *Antimicrobial Agents and Chemother.* 44:51-56
(2000).
Bleul et al., *Nature* 382:829-833 (1996).

(Continued)

Primary Examiner—Rita Desai
(74) *Attorney, Agent, or Firm*—Morrison & Foerster LLP(57) **ABSTRACT**Compounds which modulate chemokine receptor activities
are disclosed. These compounds are preferably tertiary
amines comprising tetrahydroquinoline and benzimidazole.**12 Claims, No Drawings**



US006734191B2

(12) **United States Patent**
Bridger et al.

(10) Patent No.: **US 6,734,191 B2**
(45) Date of Patent: **May 11, 2004**

(54) **CHEMOKINE RECEPTOR BINDING
HETEROCYCLIC COMPOUNDS**

(75) Inventors: Gary Bridger, Bellingham, WA (US); Renato Skerlj, Blaine, WA (US); Al Kaller, Vancouver (CA); Curtis Harwig, White Rock (CA); David Bogucl, Surrey (CA); Trevor R. Wilson, Langley (CA); Jason Crawford, Vancouver (CA); Ernest J. McEachern, White Rock (CA); Bern Atsma, Langley (CA); Siqiao Nan, Richmond (CA); Yuanxi Zhou, Langley (CA); Dominique Schols, Herent (BE); Christopher Dennis, Vancouver (CA); Rosaria Maria Di Fiuri, Burnaby (CA)

(73) Assignee: AnorMED, Inc., Langley (CA)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 16 days.

(21) Appl. No.: 10/031,812

(22) PCT Filed: Sep. 17, 2001

(86) PCT No.: PCT/US01/29590

§ 371 (c)(1),

(2), (4) Date: Mar. 28, 2002

(87) PCT Pub. No.: WO02/34745

PCT Pub. Date: May 2, 2002

(65) **Prior Publication Data**

US 2003/0028022 A1 Feb. 6, 2003

Related U.S. Application Data

Provisional application No. 60/232,891, filed on Sep. 15, 2000, provisional application No. 60/234,510, filed on Sep. 22, 2000, provisional application No. 60/233,087, filed on Sep. 15, 2000, and provisional application No. 60/234,816, filed on Sep. 22, 2000.

(51) Int. Cl.⁷ C07D 215/48; C07D 215/58; A61K 31/4725

(52) U.S. Cl. 514/307; 514/311; 514/313; 514/314; 546/159; 546/164; 546/171

(58) Field of Search 546/159, 164, 546/171; 514/307, 311, 313, 314

(56) **References Cited**

U.S. PATENT DOCUMENTS

5,021,409 A 6/1991 Murrer et al. 514/183
5,583,131 A 12/1996 Bridger et al. 514/183
5,698,546 A 12/1997 Bridger et al. 514/183
5,817,807 A 10/1998 Bridger et al. 540/474
6,001,826 A 12/1999 Murrer et al. 514/183
6,365,583 B1 4/2002 MacFarland et al. 514/183

FOREIGN PATENT DOCUMENTS

WO WO 99/38514 8/1999
WO WO 00/42852 7/2000
WO WO 00/51607 9/2000
WO WO 00/56729 9/2000

OTHER PUBLICATIONS

U.S. patent application Ser. No. 60/172,153, filed Dec. 17, 1999.
U.S. patent application Ser. No. 09/111,895, filed Jul. 8, 1998.
U.S. patent application Ser. No. 09/535,314, filed Mar. 24, 2000.
Abi-Younes et al., *Clin. Res.* 86:131-138 (2000).
Alkhaib et al., *Science* 272:1955-1958 (1996).
Arai et al., *Eur. J. Haematol.* 64:323-332 (2000).
Arenburg et al., *J. Leukocyte Biol.* 62:554-562 (1997).
Aiuti et al., *J. Exp. Med.* 185:111-120 (1997).
Baggiolini, *Nature* 392:565-568 (1998).
Bajetto et al., *J. Neurochem.* 73:2348-2357 (1999).
Berger et al., *Annu. Rev. Immunol.* 17: 657-700 (1999).
Biard-Piechaczyk et al., *Virology* 268:329-344 (2000).
Blaak et al., *Proc. Natl. Acad. Sci.* 97:1269-1274 (2000).
Blanco et al., *Antimicrobial Agents and Chemother.* 44:51-56 (2000).
Bleul et al., *Nature* 382:829-833 (1996).
Bleul et al., *J. Exp. Med.* 187:753-762 (1998).
Bradstock et al., *Leukemia* 14:882-888 (2000).
Bridger et al., "Bicyclam Derivatives as HIV Inhibitors" in *Advances in Antiviral Drug Design* vol. 3, p161-229; Published by JAI press (1999); E. De Clercq (ed).
Bridger et al., *J. Med. Chem.* 42:3971-3981 (1999).
Burger et al., *Blood* 94:3658-3667 (1999).
Buttini et al., *Nature Med.* 4:441-446 (1998).
Carroll et al., *Science* 276:273-276 (1997).
Cocchi et al., *Science* 270:1811-1815 (1995).
Connor and Ho, *J. Virol.* 68:4400-4408 (1994).
Deng et al., *Nature* 381:661-666 (1996).
Donzella et al., *Nature Medicine* 4:72-77 (1998).
Dragic et al., *Nature* 381:667-673 (1996).
Egberink et al., *J. Virol.* 73:6346-6352 (1999).
Eitner et al., *Transplantation* 66:1551-1557 (1998).
Fedyk et al., *J. Leukocyte Biol.* 66:667-673 (1999).
Feng et al., *Science* 272:872-877 (1996).
Gonzalo et al., *J. Immunol.* 165:499-508 (2000).
Gupta et al., *J. Biol. Chem.* 7:4282-4287 (1998).
Herbein et al., *Nature* 395:189-194 (1998).
Hesseltgesser et al., "Chemokines and Chemokine receptors in the Brain" in *Chemokines in Diseases* published by Humana Press (1999) Herbert (ed).
Hesseltgesser et al., *Curr. Biol.* 7:112-121 (1997).
Hesseltgesser et al., *Curr. Biol.* 8:595-598 (1998).
Ishii et al., *J. Immunol.* 163:3612-3620 (1999).
Lataillade et al., *Blood* 95:756-768 (1999).
Liu et al., *Cell* 86:367-377 (1996).
Locati et al., *Annu. Rev. Med.* 50:425-40 (1999).
Ma et al., *Immunity* 10:463-471 (1999).

(List continued on next page.)

Primary Examiner—Rita Desai

(74) Attorney, Agent, or Firm—Morrison & Foerster LLP

(57) **ABSTRACT**

Compounds which modulate chemokine receptor activities are disclosed. These compounds are preferably tertiary amines comprising tetrahydroquinoline and benzimidazole.

15 Claims, No Drawings

<h2 style="margin: 0;">TRANSMITTAL FORM</h2> <p style="margin: 5px 0;"><i>(to be used for all correspondence after initial filing)</i></p>	Application Number	Patent#: 7,091,217	
	Filing Date	Issued: August 15, 2006	
	First Named Inventor	Gary BRIDGER	
	Art Unit	1625	
	Examiner Name	R. Desai	
Total Number of Pages in This Submission	9	Attorney Docket Number	391442005902

ENCLOSURES (Check all that apply)		
<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment/Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Reply to Missing Parts/ Incomplete Application <input type="checkbox"/> Reply to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____ <div style="border: 1px solid black; width: 100px; height: 50px; margin: 0 auto;"></div> <p style="text-align: center; margin: 0;">Landscape Table on CD</p>	<input type="checkbox"/> After Allowance Communication to TC <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please Identify below): Request for Reconsideration (2 pgs); Copy of Request for Certificate of Correction filed 8/30/06 (2 pages); Copy of Proposed Certificate of Correction (1 pg); Copy of Paper Denying Request (1 page); Copies of Front Pages of Patent Nos. 7,091,217 & 6,734,191 (2 pages)
<div style="border: 1px solid black; width: 100px; height: 20px; float: left; margin-right: 10px;"></div> Remarks Customer No. 25225		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT			
Firm Name	MORRISON & FOERSTER LLP		
Signature	/Kate H. Murashige/		
Printed name	Kate H. Murashige		
Date	April 19, 2007	Reg. No.	29,959